Nicholas J. Vogelzang, MD | Authors

Articles

Rationale for Phase III PROSPECT Trial in Prostate Cancer

June 12, 2018

Nicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.

MPDL3280A in Patients with Metastatic Bladder Cancer

July 10, 2014

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.